CDSCO Panel Clears Sanofi's Updated Myozyme Insert, Seeks Revision on Administration Guidance
New Delhi: The Subject Expert Committee (SEC) under the Central Drugs Standard Control Organisation (CDSCO) has recommended the approval of the updated Package Insert for Alglucosidase alfa (Myozyme 50 mg), a recombinant enzyme therapy manufactured by Sanofi Healthcare India Pvt Ltd.
However, the approval is subject to the inclusion of a critical safety instruction. The SEC has mandated that the following statement be added under Section 4.2 – Posology and Method of Administration:
“In case of any infusion-related reaction, if required, the patient should be transferred to a nearby hospital/clinical facility for treatment.”
In addition to this condition, the committee has directed the company to submit the revised Package Insert to CDSCO for further evaluation.
This recommendation follows Sanofi’s proposal for the approval of the Updated Package Insert (dated October 2024) for Myozyme 50 mg, which includes revisions in the following sections: Posology and Method of Administration, Special Warnings and Precautions for Use, Drug Interactions, Undesirable Effects, Overdose, Pharmacological Properties, Other administrative updates
These revisions are based on the updated European Summary of Product Characteristics (EU SmPC) dated 14 March 2024.
Alglucosidase alfa is a recombinant form of human acid alpha-glucosidase (rhGAA) produced in Chinese Hamster Ovary (CHO) cells. It is classified as a Hydrolytic Lysosomal Glycogen-specific Enzyme and is indicated for enzyme replacement therapy (ERT) in patients with Pompe disease (glycogen storage disease type II), including infantile-onset Pompe disease.
The recommendation was made during the SEC meeting on Endocrinology and Metabolism held on 14th May 2025, where the expert panel deliberated on Sanofi’s submission and aligned the changes with the latest regulatory standards adopted in the EU.
The firm is now required to revise and resubmit the updated insert to CDSCO in accordance with the committee’s direction.
Also Read: CDSCO Panel Approves Fabrazyme Label Update, Asks Sanofi to Submit EMA Nod
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.